575 related articles for article (PubMed ID: 34622421)
1. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
[TBL] [Abstract][Full Text] [Related]
2. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
4. Vaccines for preventing herpes zoster in older adults.
de Oliveira Gomes J; Gagliardi AM; Andriolo BN; Torloni MR; Andriolo RB; Puga MEDS; Canteiro Cruz E
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD008858. PubMed ID: 37781954
[TBL] [Abstract][Full Text] [Related]
5. Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020.
Orru' S; Bierbaum S; Enk A; Hengel H; Hoffelner M; Huzly D; Keller-Stanislawski B; Mahler V; Mockenhaupt M; Oberle D
Euro Surveill; 2023 Dec; 28(50):. PubMed ID: 38099347
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
7. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
8. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
9. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
10. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
Tavares-Da-Silva F; Co MM; Dessart C; Hervé C; López-Fauqued M; Mahaux O; Van Holle L; Stegmann JU
Vaccine; 2020 Apr; 38(18):3489-3500. PubMed ID: 31818534
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
[TBL] [Abstract][Full Text] [Related]
12. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
13. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
14. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
Safonova E; Yawn BP; Welte T; Wang C
Respir Res; 2023 Jan; 24(1):35. PubMed ID: 36709298
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
[TBL] [Abstract][Full Text] [Related]
17. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
[TBL] [Abstract][Full Text] [Related]
18. Shingrix for Herpes Zoster: A Review.
Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK
Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679
[TBL] [Abstract][Full Text] [Related]
19. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
20. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
